Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Pemafibrate (PEM) is a novel lipid-lowering drug classified as a selective peroxisome proliferator-activated receptor α (PPARα) modulator whose binding efficiency to PPARα is superior to that of fibrates. This agent is also useful for non-alcoholic fatty liver disease and primary biliary cholangitis...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zhe Zhang, Pan Diao, Xuguang Zhang, Takero Nakajima, Takefumi Kimura, Naoki Tanaka
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-07-01
Edice:	Biomedicines
Témata:	β-oxidation pemafibrate PPARα triglycerides liver FGF21
On-line přístup:	https://www.mdpi.com/2227-9059/10/7/1667
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!